Cargo Therapeutics Inc
Company Profile
Business description
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
Contact
835 Industrial Road
Suite 400
San CarlosCA94070
USAT: +1 650 379-6143
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
167
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.10 | 3.90 | -0.04% |
| CAC 40 | 7,671.29 | 70.95 | -0.92% |
| DAX 40 | 23,385.68 | 313.44 | -1.32% |
| Dow JONES (US) | 42,515.09 | 317.30 | 0.75% |
| FTSE 100 | 8,835.67 | 39.55 | -0.45% |
| HKSE | 23,980.30 | 80.69 | -0.34% |
| NASDAQ | 19,701.21 | 294.39 | 1.52% |
| Nikkei 225 | 38,536.74 | 225.41 | 0.59% |
| NZX 50 Index | 12,639.35 | 50.78 | -0.40% |
| S&P 500 | 6,033.11 | 56.14 | 0.94% |
| S&P/ASX 200 | 8,541.30 | 7.10 | -0.08% |
| SSE Composite Index | 3,387.40 | 1.32 | -0.04% |